Total | OC | aMCI | ADD | SVCI | CAA | YC | |
---|---|---|---|---|---|---|---|
N | 580 | 149 | 212 | 134 | 58 | 12 | 15 |
Age (years) | 69.8 ± 11.0 | 69.6 ± 7.7 | 70.0 ± 8.3 | 70.2 ± 11.0 | 77.4 ± 8.5*,†,$ | 76.8 ± 6.9 | 32.5 ± 3.9*,†,$ |
Female sex | 362 (62.4) | 98 (65.8) | 119 (56.1) | 90 (67.7)† | 44 (74.6)† | 6 (50.0) | 6 (40.0)*,$,^ |
APOE4 carrier | 214 (36.9) | 38 (25.5) | 85 (40.1)* | 75 (56.4)*,† | 12 (20.3)†,$ | 1 (8.3)†,$ | 3 (20.0)$ |
PET positivitya | 280/578b (48.4) | 17 (11.4) | 119 (56.1)* | 113/133 (85.0)*,† | 22 (37.9)*,†,$ | 9/11 (81.8)*,^ | 0 (0.0)†,$,^,# |
MMSE | 24 ± 5.4 | 27.8 ± 2.5 | 22.5 ± 3.3* | 18.5 ± 5.3*,† | 22 ± 5.4*,†,$ | 21 ± 7.3*,$ | N/A |
Plasma Aβ42 | 56.9 ± 16.2 (n = 577) | 60 ± 14.4 | 56.1 ± 16.3 | 51.7 ± 15.5* | 64.8 ± 18.2†,$ | 55.7 ± 20.3 | 52.2±5^ |
Plasma Aβ40 | 217 ± 58.2 (n = 572) | 215.8 ± 52.5 | 216 ± 55 | 210.8 ± 60.3 | 241.7 ± 68.1*,†,$ | 237.1 ± 86.4 | 184.4 ± 15.6^ |
Plasma Aβ42/Aβ40 | 0.27 ± 0.06 (n = 572) | 0.28 ± 0.05 | 0.27 ± 0.05* | 0.26 ± 0.08* | 0.28 ± 0.07 | 0.24 ± 0.03 | 0.28 ± 0.03 |